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ABSTRACT 
Recent advances in the field of biotechnology have led to products containing enzymes, antibodies, and other biological 
agents for suitable use as pharmaceuticals for treatment of many diseases and vaccines for prevention purposes of broad range of 
infectious diseases. Poliomyelitis is one of serious disease caused by a virus, affecting the nervous system and resulting in paralysis in 
infant survivors. Oral Polio vaccine is used worldwide to eradicate the polio. Numerous challenges facing polio eradication continue to 
arise and differ from region to region, but one of such challenge of the Oral Polio vaccine is vaccine derived polio cases known as 
vaccine derived polioviruses and vaccines associated polio cases known as vaccine-associated paralytic poliomyelitis. Inactivated Polio 
vaccine is one of the better options to eliminate and/or prevent these cases. On the basis of past literature, we are summarized here 
current development in polio vaccines after applying different technology and administrative routes. Furthermore, it is necessary to 
improve education, so people understand the basic concept of alternative vaccines and their different administration routes, thereby 
assisting in creating a basic understanding of polio vaccine and its vaccinations. Communication strategies should, therefore, be aimed 
at increasing awareness of poliomyelitis as a real health threat and educating the populace about the safety of the vaccine. Polio 
eradication partners should collaborate with other agencies and ministries to improve total primary healthcare packages to address 
identified unmet health and social needs.  
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INTRODUCTION 
 
Polio (also known as poliomyelitis) is a highly 
contagious disease caused by a virus that attacks the nervous 
system. Children younger than 5 years old are more likely to 
contract the virus than any other group. According to the World 
Health Organization (WHO), 1 in 200 polio infections will result 
in permanent paralysis. Poliovirus (PV) is a member of the 
Picornaviridae family in the order of Picornavirales and a 
causative agent of poliomyelitis. PV is formed in non-enveloped 
capsid and has a single-stranded positive-sense RNA genome [1, 
2]. The disease, caused by any one of three serotypes of 
poliovirus (PV1, PV2, and PV3,) has no specific treatment, but 
can be prevented through vaccination. Viruses, vaccines & 
disease Global eradication of polio are within grasp. Only some  
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DOI: 
countries are currently considered endemic for polio because 
they have never eliminated indigenous polio viruses. However, 
thanks to the global polio eradication initiative in 1988, 
America, Europe, western pacific Southeast Asia regions are 
now certified polio-free. overall reduction in global incidence of 
cases has been more than 99% since the eradication efforts 
begun in 1988 when an estimated 350,000 persons were 
paralyzed by wild polio viruses (WPVs), there are still a few 
hundred cases of WPV-related paralysis each year (416 cases in 
2013 and 359 in 2014) [1]. These cases are occurring both in the 
endemic countries as well as in countries re-infected via 
importations. PV1 is the most common form encountered in 
nature and is highly localized to regions in Pakistan and 
Afghanistan. PV2 was declared eradicated in September 2015 
after last being detected in October 1999 in Uttar Pradesh, India, 
and PV3 has not been seen since its detection in parts of Nigeria 
and Pakistan in 2012. All PVs can be transmitted person to 
person via direct contact, contaminated food, or other fomites. 
Poliovirus infection is asymptomatic or mild in about 95% of 
infected individuals, and approximately 0.5% of those may 
present paralytic disease. However, due to its highly contagious 
nature, poliovirus infection can affect large populations. 
 
In 2011, Singh and Kumar summarized complete 
information related to history, taxonomy, properties, clinical 
manifestation, and pathogenesis of polio viruses as well as 
conventional and hypothetical future vaccines in the post 
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vaccination era [3]. Currently, two vaccines are using for 
vaccination purpose; live attenuated oral poliovirus vaccine 
(OPV) and inactivated poliovirus vaccine (IPV) are used 
throughout the world to protect against polio. In 121 countries 
[2], OPV is used instead of IPV for several reasons: OPV costs 
substantially less than IPV [4]; primary immunization with OPV 
induces superior intestinal immunity compared with IPV and 
thus has the potential to better prevent transmission of wild 
viruses; OPV confers contact immunity through passive 
immunization of unvaccinated persons from viruses shed by 
vaccines; and OPV is administered in oral drops, which are 
easier to administer than IPV injections and easier to store and 
transport. Despite these advantages, most developed countries 
have transitioned to IPV, primarily because OPV has the major 
disadvantage of causing paralytic disease in rare cases [5]. It can 
cause vaccine-associated paralytic poliomyelitis (VAPP) in 
vaccine recipients and close contacts at an estimated rate of 
about 4.7 per million births (range: 2.4–9.7) globally [6]. 
Typically, the risk of VAPP is highest with the first dose of OPV 
in industrialized countries – about 6.6-times higher for first-
time recipients than those receiving subsequent doses whereas 
in developing countries the risk of VAPP can be lower for first 
dose recipients [7]. Data from India show that VAPP is largely 
associated with second or subsequent doses of OPV, indicating 
that the age of onset for VAPP is higher in lower-income settings 
[8]. Moreover, the live vaccine virus also can mutate in ways that 
confer the transmissibility and neurovirulence properties of 
wild viruses, leading to polio outbreaks caused by these altered 
viruses known as circulating vaccine derived polioviruses 
(cVDPVs). There has been an average of 76 reported cases of 
cVDPVs annually between 2005 and 2013 [1].  
 
Oral Polio Vaccine has successfully eliminated WPV 
from major part of the world. However, circulating vaccine 
derived polioviruses (VDPVs) and vaccine-associated paralytic 
polio (VAPP) have exposed its shortcomings and paved the way 
for introduction of IPV in to the global vaccination schedules. 
The polio eradication and endgame strategies reflect the 
complimentary roles of the two polio vaccines in tackling the 
threats posed by wild and vaccine polioviruses [9]. Development 
of potent, safe and effective vaccines against polio is still under 
process by using advanced technologies, different administrated 
routes and through various vaccinated schedules anywhere in 
world. Therefore this review comprises the update information 
related to polio vaccines, vaccination schedule and their 
administrated routes in current scenario. The review will 
helpful to nourish technical knowledge of researchers, 
academician, scientist and other professionals, who are engaged 
in this research field.  
 
Current polio vaccines: 
(a) Oral polio vaccine (OPV): 
This vaccine was developed in 1958 by Dr. Albert 
Sabin. Sabin attenuated the wild type poliovirus by passaging 
the virus in monkey kidney epithelial cells [10, 11]. Administration 
of OPV mimics the immune response to natural exposure to 
WPV generating both humoral and mucosal immunity [7]. IgM 
antibody becomes detectable as early as 2–3 days after 
infection, usually disappearing after 2–3 months, while IgG 
becomes the predominate antibody and may last for life [7]. 
Because it is easily administered for induce the long-lasting 
immunity. OPV has been the vaccine of choice throughout the 
developing world, and forms the backbone of the global polio 
eradication effort. There are three formulations of OPVs are: 
tOPV containing Sabin strains of all three poliovirus serotypes; 
bOPV containing Sabin strains for types 1 and 3; and 
monovalent OPV (mOPV), which has two subtypes for serotypes 
1 (mOPV1) and 3 (mOPV3). In addition, monovalent OPV for 
serotype 2 (mOPV2) is available for research purposes as well 
as for response procedures should there be an outbreak of 
poliovirus type 2. In a randomized, doubleblind, controlled trial 
in India, the cumulative seroconversion rates to serotype 1 
following two doses at birth and at 30 days, were 90% for 
mOPV1 and 86% for bOPV compared with 63% for tOPV [12]. For 
serotype 2, the seroconversion rates were 90% for mOPV2 
compared with 91% for tOPV, and for poliovirus type 3, 
seroconversion rates were 84% for mOPV3 and 74% for bOPV 
compared with 52% for tOPV [12]. Currently, bOPV is in routine 
immunization globally. 
 
(b) Inactivated polio vaccine (IPV):  
In current scenario, there are two different IPV 
developed, which can be differentiate on the basis used viral 
vaccine strains. First IPV was developed against polio by Dr. 
Jonas Salk in 1952 and formaldehyde was used for inactivation 
of wild polio viruses and the vaccine is also called Salk vaccine. 
The IPV contains strains of all three serotypes of poliovirus 
(Type 1, 2 & 3), originally grown in monkey kidney cell culture 
and inactivated by exposure to formaldehyde [13, 14]. The 
following table shows strains of IPV that was discovered and 
used. The vaccine is a clear, colorless sterile suspension for 
subcutaneous injection. Clinical trials of IPV began in 1954 and 
results were dramatic; the cases of polio in the vaccinated test 
groups fell amazingly, and permission produces protective 
antibodies in the blood (serum immunity) [13]. After 2 doses of 
enhanced potency IPV (eIPV), high levels of serum neutralizing 
antibodies to all 3 types of polioviruses appears in 94-100% of 
individuals. IPV was shown to effectively immunize and protect 
against poliomyelitis [15].  
 
Second IPV containing the attenuated Sabin vaccine 
strains of poliovirus (sIPV) would reduce the potential severity 
of the consequences of intentional or unintentional release of 
virus from an IPV manufacturing facility [16]. Thus sIPV is seen as 
more appropriate for manufacture in countries such as China, 
India, and Indonesia, where OPV is already manufactured. The 
vaccine is a clear, colorless sterile suspension for subcutaneous 
injection. Clinical trials of IPV began in 1954 and results were 
dramatic; the cases of polio in the vaccinated test groups fell 
amazingly, and permission produces protective antibodies in 
the blood (serum immunity) [13]. After 2 doses of enhanced 
potency IPV, high levels of serum neutralizing antibodies to all 3 
types of polioviruses appears in 94-100% of individuals. This 
serum immunity prevents the spread of the virus to the CNS and 
provides protection against polio paralysis. The enhanced 
potency IPV induces mucosal immunity by inhibiting pharyngeal 
acquisition of poliovirus. The intestinal acquisition, yet the 
extent of mucosal immunity induced by IPV are far less than 
OPV. Therefore, while OPV can prevent the spread of wild 
poliovirus that indicate that IPV is a less reliable vaccine. The 
current formulation of IPV induces close to 100% 
seroconversion rates with high antibody titers to the three 
poliovirus serotypes after a series of three doses, when 
administered in schedules in which the last dose is administered 
at 6 months of age or older [17]. Lower rates of seroconversion 
are seen in the presence of high levels of maternally derived 
antibody. Administration of IPV at older ages, giving a chance 
for maternally derived antibody to wane, is associated with 
higher levels of seroconversion [13]. Currently accepted 
correlates of protection for IPV containing vaccines require 
neutralizing antibody levels at or above a 1:4 to 1:8 dilution 
threshold [19]. IPV shows a similar effect to OPV in inducing 
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pharyngeal immunity, but has limited effect in inducing primary 
intestinal immunity when administered alone and thus, IPV is 
equivalent to OPV in reducing oral shedding following an OPV 
challenge but is inferior to OPV in reducing intestinal shedding 
when used for primary immunization in subjects who have not 
previously been exposed to OPV [20]. In fact, the proportion of 
persons who shed virus in stool following an OPV challenge in 
IPV vaccines is similar to the proportion who shed following a 
dose of OPV to unvaccinated persons. However, despite 
shortcomings in induction of intestinal immunity following a 
primary series, IPV has been shown to reduce both the duration 
of shedding and the amount of virus shedding in the stool (with 
a range between studies of 63 and 91% reduction in the total 
amount of virus shed). This implies that IPV may reduce 
transmission even in places where fecal–oral spread is thought 
to be the predominant mode of transmission [21, 22]. IPV alone 
terminated polio transmission in several Nordic countries of 
Europe (e.g., Sweden and The Netherlands). It is unclear 
whether the reason for this success is because oral–oral 
transmission is the predominant mode of transmission in these 
countries or if there was additional impact from reduction in 
quantity and duration of fecal shedding induced by IPV. 
Whether IPV alone in a developing country population in whom 
fecal–oral transmission is thought to predominate, can 
terminate transmission of wild or vaccine viruses is not clear. 
Since its development, IPV has been one of the safest vaccines in 
humans, whether used alone or in combination vaccines [23, 24]. 
IPV is offered as a standalone Vaccine as well as in combination 
vaccines for primary immunization (ten products) and for 
boosters (>five products) [20]. Since early in the development of 
IPV, it has been co-administered with diphtheria, tetanus and 
pertussis vaccine (DTwP and DTaP), Haemophilus influenza type 
b vaccine (Hib) and hepatitis B vaccine. No serious adverse 
events have been causally associated with IPV. When used 
alone, IPV is well tolerated. 
A recent review of the US Vaccine Adverse Events 
Reporting System (VAERS) from 1999 to 2012 also reported 
that there were no concerning safety issues of adverse events 
for IPV [25]. A 2014 systematic review of the literature on the 
safety of routine vaccines recommended for children in the USA 
found insufficient evidence to report any association between 
IPV and sensitivity to food allergens (as one post-licensure 
study reported) and that serious adverse events are extremely 
rare for all routine vaccines [26]. Moreover, IPV administered 
before OPV reduces VAPP cases compared with OPV alone. In 
2014, the Global Advisory Committee on Vaccine Safety 
declared IPV and IPV-containing vaccines as having an excellent 
Safety profile, based on available data [25]. 
 
Sequential schedule of polio vaccines: 
Considering the history of inactivated and live polio 
vaccine development, and later their public use globally, any 
discussion on the superiority of one over the other is replete 
with passionate arguments. Both these vaccines have certain 
merits and demerits yet they proved to be having a great 
complimentary role as far as polio eradication effort is 
concerned. Table 1 provides benefits and limitation of these two 
polio vaccines on the basis of comparable attributes. 
 
Table No. 1: Benefits and limitations of current polio vaccines 
S. No. Attributes OPV IPV 
1 Form of vaccine Liquid suspension Freeze dried powder 
2 Route of administration Oral IM injection 
3 Thermo stability Heat sensitive Heat and freeze sensitive 
4 Administration schedule Heat sensitive At least 03 doses 
5 Humoral immunogenicity Good Good 
6 Intestinal immunogenicity Good Poor 
7 Method of administration Routine Immunization Routine Immunization 
8 Safety VAPP, VDPVs No safety issues 
9 Cold storage space Small Small (<5–7% of total volume) 
10 Cost US$0.15/dose US$1/dose 
11 Waste Management No risk Sharp disposal 
 
(a) IPV alone: 
Although IPV alone has shown limited effect in 
inducing primary intestinal mucosal immunity, it has shown 
promise in the area of priming for a systemic immune response. 
A single IPV dose generally seroconverts a proportion of 
vaccines but induces immune memory (primes) in the majority 
of the remaining seronegative children. Data on the added 
protection against paralysis conferred by priming are not 
conclusive. In a study from Cuba, among those who did not 
seroconvert after one dose of IPV, 98% had a priming response 
(they developed significant antibody responses within 7 days of 
subsequent exposure) after one dose of IPV [15]. On the other 
hand, in a case-control study of a WPV1 outbreak in Senegal, 
effectiveness against paralytic polio was estimated to be 36% 
after one dose and 89% after two doses, values more compatible 
with per dose IPV seroconversion rates than with priming rates 
[26].  
 
 
(b) OPV alone: 
Although OPV alone is also a alternative way for 
vaccination and protective immunity through inducing 
intestinal mucosal immunity. Two major adverse effects of OPV 
are due to reversion of vaccine viruses to neurovirulece and 
transmissibility [27]. The first, VAPP, primarily occurs due to loss 
of attenuating mutations and reversion to neurovirulence 
during replication of the vaccine virus in the gut [28]. The second 
major adverse event associated with OPV is VDPV which was 
recognized relatively late in the process of GPEI operations in 
the Dominican Republic and Haiti during 2000-2001 [29]. They 
arise due to mutation and recombination with other 
enteroviruses in the human gut and are usually 1-15% 
divergent from the parent vaccine virus. The VDPV cases appear 
in communities with very low rates of coverage with OPV. Some 
VDPVs become efficient transmitters – they circulate in children 
and cause polio – if 2 cases of polio are caused by one lineage it 
called ‘circulating VDPV’ (cVDPV). The mutations accumulate at 
a relatively constant rate - around 1% a year. The outbreaks 
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caused by VDPVs had biological properties indistinguishable 
from those of wild poliovirus [29]. According to a recent review; 
the global risk of VAPP is estimated to be around 4.7 cases per 
million births (range, 2.4-9.7). 
 
(c) OPV before IPV: 
Immunogenicity of IPV when given in an OPV exposed 
population has been studied extensively. A single dose of IPV 
administered to infants in Côte D’Ivoire previously vaccinated 
with a three-dose primary schedule of tOPV was significantly 
more effective than an additional dose of tOPV in achieving 
seroconversion at both 6 and 9 months in subjects who were 
seronegative after the primary series [30]. More recently, a 
multiarm trial in Moradabad, India compared a supplemental 
dose of IPV at 6–9 months to children who had completed a 
primary series of tOPV plus multiple doses of mOPV, to boosting 
with a standard and higher potency type 1 mOPV [31]. As in the 
Côte D’Ivoire study, higher rates of seroconversion in baseline 
seronegative subjects and increased titers in baseline 
seropositive Subjects were noted in the subjects receiving IPV 
compared with children who received an additional dose of 
OPV. 
 
Two recent studies done in India have shown that one 
dose of IPV given to prior recipients of OPV boosts intestinal 
immunity for types 1and 3 [32, 33]. In children with history of 
multiple doses of OPV, the proportion of children excreting the 
challenge poliovirus was significantly lower for those given a 
booster dose of IPV followed by a bOPV challenge than those 
who did not receive any booster prior to the bOPV challenge [33]. 
The duration of this boost in intestinal immunity is, however, 
unknown. A dose of OPV given at birth increases seroconversion 
rates [34] and provides an opportunity to induce mucosal 
protection in infants before they are exposed to enteric 
pathogens. WHO recommends a birth dose of OPV for polio-
endemic countries and countries at high risk for importation 
and subsequent spread [35]. 
 
(d) IPV before OPV: 
Vaccination regimens employing sequential 
combinations of IPV and OPV have been utilized in a number of 
countries, including in the USA. In developed countries where 
elimination of polio was achieved, VAPP was seen as a major 
public health problem and resources were available to address 
the increased costs of using IPV in a sequential IPV to OPV 
schedule. The intent of this schedule was to acquire the 
advantages of both IPV and OPV while minimizing adverse 
reactions: initial immunization with IPV to promote humoral 
immunity, which gives children protection from VAPP, and 
subsequent OPV vaccination to induce higher levels of intestinal 
immunity and maintain population-level protection. In Hungary, 
a country with a significant problem with VAPP cases [36] a 
sequential schedule comprising one dose of IPV followed by 
OPV led to a complete disappearance of VAPP [30, 31]. Another 
study in Hungary found that one or three doses of IPV followed 
by three doses of OPV resulted in individual protection against 
paralytic poliomyelitis as well as reduced cases of VAPP in the 
population [37, 38]. Additional experiences in India and the USA 
have shown that receiving IPV before OPV appears to protect 
against VAPP [12, 34, 36]. In addition, the sequential schedule of IPV 
followed by OPV in developed country settings achieved high 
seroconversion rates, with optimal effect obtained using two 
doses of IPV followed by two doses of OPV, a regimen that also 
produced intestinal immunity comparable to three doses of OPV 
[39]. The efficacy of this strategy has also been studied in the 
developing world: a trial of IPV followed by OPV in Guatemalan 
infant’s demonstrated robust humoral immunity even after only 
two doses of IPV [40]. Also, use of mOPV in an outbreak control 
setting in a population who received a dose of IPV is likely to 
lead to higher immunity levels than a single dose of mOPV in a 
completely susceptible population, as the IPV-vaccinated 
population would already be partially protected with the 
existence of neutralizing antibodies from previous 
administration of IPV [39, 41]. 
 
Polio end game and its barriers: 
Led by WHO, the United Nations Children’s Fund 
(UNICEF), Rotary International and the CDC among other 
organizations, the Global Polio Eradication Initiative (GPEI) has 
developed the Polio Eradication and Endgame Strategic Plan 
was aimed to wipe out the last cases of polio from all causes by 
2018 [35]. Because type 2 virus accounts for more than 95% of 
cVDPV outbreaks detected in recent years and approximately 
30% of VAPP cases, a critical intermediate step to replace the 
trivalent OPV (tOPV), which with an aim of reviewing current 
scenario of polio vaccine this article is written, protects against 
types 1, 2 and 3, with a bivalent OPV (bOPV), which protects 
against types 1 and 3. The plan also calls for the addition of at 
least one dose of IPV (all currently licensed IPV is trivalent and 
protects against all types of polio) in routine immunization (RI) 
programs by 2015 in the OPV-only countries. IPV will provide 
immunity to a substantial proportion of the population [42] 
during this proposed OPV switch as well as during complete 
OPV withdrawal post-eradication in case of the possible 
emergence of type 2 cVDPVs, as well as in case of potential 
breaks in laboratory containment of wild or vaccine viruses. 
Such a plan is expected to change the landscape of global polio 
vaccine use in an incredibly short span of time The 2013–2018 
strategic plan is expected to cost US$5.5 billion over the course 
of the program with continued investment by countries, but 
promises to yield up to US$25 billion in additional net benefits 
over the next 20 years. Substantial funding will be required 
throughout the end game to support core program costs, 
planned and supplemental immunization activities, surveillance, 
emergency response and containment. Total eradication of polio 
will lead to major reductions in public health spending on 
medical care, vaccine financing and programmatic costs once 
cases are reduced to zero and control activities can be scaled 
back [35]. 
 
While it has been shown that IPV integrated into RI 
programs will indeed reduce the prevalence of paralytic polio 
within a population, uncertainties remain on IPV’s role in 
impacting transmission as part of a global polio eradication 
strategy as evident with the situation in Israel in 2013–2014 
with more than a year of WPV1 isolation in sewage samples as 
discussed before [43]. On the other hand, Yogyakarta in Indonesia 
also switched to an all IPV schedule and has not detected any 
VDPVs since the chang. Yogyakarta had very high coverage and 
improved economic and public health infrastructure which may 
limit generalizability of this case to the low-income settings. 
Also, the force of infection of a vaccine virus may be different 
than that of a WPV, and IPV may be more effective against the 
former than the latter. It will be important to continue to 
monitor for circulation of type 2 viruses in particular as IPV 
becomes the only inducer of immunity to type 2 with switch of 
tOPV to bOPV. For countries with a routine Expanded Program 
on Immunization (EPI) schedule of 6, 10 and 14 weeks and 
deciding to give only one dose of IPV, that dose should be given 
at 14 weeks of age, at the same time DTP3 is normally 
administered. Addition of IPV does not impact the use of OPV at 
this time, which should be continued. Thus, for a child the dose 
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of IPV would usually be administered with the third dose of OPV 
for countries without a birth dose of OPV or fourth dose of OPV 
in countries with a birth dose. OPV-only countries have the 
flexibility to consider alternative schedules (such as 6, 10 and 
14 weeks, 2, 3 and 4 months or 2, 4 and 6 months) and more 
than one IPV dose but are encouraged to develop a plan for IPV 
introduction by the end of 2014, based on tiered priority of 
countries related to risk of cVDPV emergence and spread [33]. 
Introduction of IPV in RI preceding the global withdrawal of 
Sabin type 2 is expected to have several important implications: 
 
New Polio Vaccine Research: 
Kind of vaccine desired for the end game and post 
eradication period would ideally have high humoral and 
intestinal immunity, long duration of protection, low cost, 
simple administration, widespread safe production, limited 
waste and heat and freeze stability, among other characteristics  
 
(a) Monovalent IPV-2: 
Currently available IPV is formalin inactivated 
trivalent vaccine comprising the three poliovirus serotypes, type 
1, 2, 3 and is manufactured based on enhancements of methods 
developed in the 1950s by Jonas Salk. Following the 
development of the D-antigen (D-Ag) potency assays in the 
1970s, the D-Ag content of 40, 8 and 32 D-Ag units for poliovirus 
type 1, 2 and 3, respectively for current IPV was established 
based on the historic immunogenicity studies by Salk [44-46]. 
Based on the data from the dose ranging studies and as a 
compromise between protective immune response in children 
and the quantity of vaccine that could be optimally 
manufactured with cost considerations, WHO defined in 1981 
the 40-8-32 D-Ag units composition as the specification for the 
antigenic content for all trivalent IPV formulations [47]. Under 
the best of circumstances if only a single dose of IPV is used at 4 
months of age, a study in Cuba found only 63% of recipients 
seroconvert to type 2. A higher antigen content monovalent IPV 
type 2 (m-IPV2) could be an option for the polio end game 
immunization strategies as a source of more effective primary 
immunogenicity against type 2, particularly during the period 
when bOPV would be used in RI. For this purpose, Bilthoven  
Biologicals company has formulated the m-IPV2 with an antigen 
content (type 2) of 32 D-Ag units, four-times the current dose of 
type 2 in the trivalent IPV. A Phase I study on safety in adults 
with m-IPV2 is now completed, and a Phase II study on safety 
and immunogenicity in infants is underway with this product 
(Table 3). Results from these studies are expected to be 
available by 2015, and should provide important information on 
any potential role of m-IPV2 in the polio eradication end game 
[48, 49]. 
 
(b) Adjuvant-IPV: 
To support incorporation of IPV into global 
immunization programs, a range of approaches are being 
supported with goals of reducing the cost and increasing the 
supply of IPV. This includes developing formulations of IPV 
combined with an adjuvant to improve the immune response 
and decrease the amount of polio antigens needed. Adjuvant 
have been shown to influence factors such as onset, magnitude, 
duration and/or quality of the immune response [50, 51]. Such 
enhanced immune responses could translate into reduction in 
antigen dose or in the number of immunizations required, 
which could translate into the reduction of the costs of 
vaccination. Some adjuvants have also been shown to induce 
different types of immune responses, such as the enhancement 
of intestinal immune responses [52], which would improve the 
chances of interrupting transmission of both WPVs and VDPVs. 
In light of the increasing demand for IPV to be used to boost 
humoral immunity in individuals to protect against paralytic 
disease during the planned switch from tOPV to bOPV and all 
OPV cessation by 2019, IPV adjuvantation strategies have 
prioritized. A high priority has been given to efforts to evaluate 
and, if warranted, to clinically advance IPV formulations 
adjuvanted with aluminum salts, given that aluminum adjuvants 
have been shown to promote dose-sparing, have a broad safety 
database and are already widely used in childhood vaccines, 
including IPV containing combination vaccines. Furthermore, 
regulators have already approved aluminum as an adjuvant for 
other vaccines such as DTP, having considered aluminum salt 
adjuvants as both safe and effective. Planning for clinical studies 
to evaluate such a formulation with Salk IPV is currently 
ongoing with funding support from the Bill and Melinda Gates 
Foundation. As another example, an aluminum hydroxide-
adjuvanted Sabin IPV has also recently been clinically evaluated 
[53]. The development of IPV adjuvanted with novel adjuvants 
that may enhance intestinal mucosal immunogenicity is also 
being explored as an important risk-mitigating strategy because 
some of the adjuvants, such as double-mutant heatlabile 
enterotoxin (‘dmLT’), have been shown in studies conducted 
with other vaccine formulations to enhance mucosal immune 
responses in the intestine [54, 55]. The hope is that the adjuvanted 
IPV would have the potential not only to prevent paralytic 
disease (which can already be accomplished with the current 
unadjuvanted IPV formulations) but also to significantly 
enhance intestinal mucosal immunity and thereby reduce the 
risk for shedding and environmental transmission of 
polioviruses. Due to the anticipated more complex and thus, 
longer regulatory pathway required for a formulation involving 
a novel adjuvant such as dMLT, the regulatory approval timeline 
of such an IPV product would be anticipated to be several years 
after OPV cessation.  
 
(c) New OPV formulations: 
Vaccination against polio is likely to continue for at least 5 
years after cessation of all OPV to ensure that both WPV and 
VDPV are extinct, and do not re-establish circulation. Current 
plans are to use mOPV2 in SIAs to control outbreaks should a 
WPV2 or cVDPV2 be found to be circulating in the post-
eradication era. A new OPV-2 that is genetically more stable 
than Sabin type 2 could avert the unwanted potential for 
generating new type 2 cVDPVs with mass use of mOPV2, by 
significantly reducing the risk of neurovirulence and 
transmissiblilty. Several approaches are being undertaken to 
develop new and safer type 2 OPVs that are significantly less 
likely to cause VAPP or cVDPVs. Some of the concepts being 
explored alone or in combination include [56-64]: 
 
1. Stabilizing the Sabin-2 attenuation phenotype by modifying 
the nucleotides in the 5′UTR; 
2. Ensuring the maintenance of the modified 5′UTR or 
increasing attenuation by relocation of a genetic element 
(cre), which is required   for replication, to the 5′UTR of the 
viral genome; 
3. Reducing the rate of mutation in the viral genome through 
the selection of mutations that increase the fidelity of RNA-
dependent RNA polymerase; 
4. Attenuating the virus by modifying the nucleotide sequence 
of the viral capsid by a method called codon deoptimization 
such that the amino acid sequence of the viral polyprotein 
is unchanged. 
 
Successful development of a genetically stable type 2 
OPV could pave the way for developing genetically stable 
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vaccines against serotypes 1 and 3. If a new OPV-2 could be 
successfully developed, it would be an important tool for the 
control and elimination of cVDPVs in the concluding phases of 
the polio eradication initiative. 
 
(d) Sabin IPV: 
As the global eradication program moves closer to the 
achievement of zero virus transmission, and cessation of all OPV 
use, production facilities for IPV would possibly be the only 
source of WPVs. Therefore, an additional measure to minimize 
the risk of reintroduction of WPV from IPV manufacturing 
facilities would be to develop IPVs that are formulated from an 
attenuated live poliovirus [65]. IPV is usually made from WPV 
strains such as Mahoney (Salk type 1), MEF-1 (Salk type 2) and 
Saukett (Salk type 3) which are grown in Vero cell culture or in 
human diploid cells [66].Successful development of IPV based 
on the attenuated Sabin virus strains has led to the licensure of 
the Sabin IPV in Japan and subsequent introduction of DTP-
Sabin IPV formulations in routine immunization program in the 
country [65]. Although still a risk, Sabin polioviruses are much 
less likely to cause problems if released accidentally from a 
production laboratory given that they are less virulent and less 
transmissible than WPVs. However, the costs, efficacy and 
feasibility of large-scale production are currently being 
evaluated, and further research to explore operational and 
immunological impact of Sabin IPV and standardization of 
assessment of antigenic content would be important to inform 
near- and post-eradication vaccination policies [65, 66]. 
 
(e) Synthetic polio vaccine: 
Poliovirus (PV)-like particles from all three PV 
serotypes, containing either the wt coat protein or coat proteins 
with stabilizing mutations, were successfully expressed in 
plants. These were generated by co-expression of the structural 
polyprotein P1 and the proteinase 3CD. Sufficient quantities of 
purified particles could be obtained for structural and 
immunological analysis. Mice carrying the gene for the human 
PV receptor were protected from wild-type PV when immunized 
with the plant-made stabilized PV vlps. Structural analysis of the 
stabilized mutant of PV3 at 3.6 A resolution revealed a structure 
almost indistinguishable from wild-type PV3, with the 
stabilizing mutations having no effect on the antigenic surface of 
the particle. To make the product more attractive to the vaccine 
industry, tobacco BY-2 cells have been successfully tested for 
the transient expression of the above-mentioned PV mutant vlps 
using the cell-pack method. 
 
(f) Transient-Expresion: 
1. Use of virus free particle (eukaryotic): 
PV vaccines have systematically reduced polio virus 
spread and paved the way for eradication. Immunization will 
continue posteradication to ensure against reintroduction of the 
disease, but there are biosafety concerns for both OPV and IPV. 
They could be addressed by the production and use of virus-free 
virus-like particle (VLP) vaccines that mimic the “empty” 
capsids (ECs) normally produced in viral infection. Although ECs 
are antigenically indistinguishable from mature virus particles, 
they are less stable and readily convert into an alternative 
conformation unsuitable for vaccine purposes. Stabilized ECs, 
expressed recombinantly as VLPs, could be ideal candidate 
vaccines for a polio-free world. However, although genome-free 
PV ECs have been expressed as VLPs in a variety of systems, 
their inherent antigenic instability has proved a barrier to 
further development. In a study, thermally stable ECs of type 1 
PV (PV-1) selected. The ECs are antigenically stable at 
temperatures above the conversion temperature of wild-type 
(wt) virions. We have identified mutations on the capsid surface 
and in internal networks that are responsible for EC stability. 
With reference to the capsid structure, we speculate on the roles 
of these residues in capsid stability and postulate that such 
stabilized VLPs could be used as novel vaccines [67]. 
 
2. Plant as a expression system (eukakatyotic): 
Two different ways to express pharmaceuticals, 
including VLPs, in plants and suspension cultures: (i) stable 
transformation of either the nuclear or plasmid genome or (ii) 
transient expression. Transient expression uses the soil 
bacterium A. tumefaciens which causes crown gall disease, to 
deliver foreign sequences to plants. Since the 1970`s it has been 
known that this gram-negative bacterium can transfer a part of 
its special Ti (tumor-inducing) plasmid into the plant cell where 
it then integrates into the host genome [68]. The gene of interest 
is inserted into the T-DNA region of a binary plasmid which will 
then be expressed in the plant cell. This allows screening and 
production in a matter of days. However, expression is limited 
to the infiltrated tissue but large-scale production and 
processing has been developed [69]. Transient expression is not 
as tightly regulated as transgenic plants; mainly because the 
gene of interest is not introduced into the germline and hence 
not heritable and also transmission through pollen is 
impossible. Transient expression is more established and 
accepted with Medicago`s influenza vaccine currently 
undergoing phase 3 clinical trials [69]. It allows the rapid 
production of high protein yields ideal for emergencies such as 
vaccines and prophylactic antibodies, as seen in the recent 
outbreak of Ebola virus disease in West Africa [70]. 
 
Administration routes of polio vaccines: 
Vaccine delivery is a crucial aspect in addressing the 
challenges in vaccine development as it encompasses both 
administration of the vaccine formulation to specific target sites 
and delivery of the antigen to and activation of relevant cells of 
the immune system [71]. Since alternative delivery methods and 
improved formulations have the potential to make vaccine 
delivery easier and safer, several alternatives for needle-based 
vaccination are currently being developed. Needle-free delivery 
approaches are preferred for multiple reasons; 
 
I. It might reduce costs since it does not require trained 
health-care personnel. 
II. Logistic problems associated with the supply and disposal 
of syringes and needles and safety risks related to injection 
would be diminished [72]. 
III. Vaccine logistics could be further simplified by the use of 
dried vaccine formulations, which can be smaller and 
lighter than liquid formulations when packaged correctly. 
IV. The independence of a cold-chain for storage and 
distribution could further reduce the costs. 
 
Besides the route of administration, other aspects 
need to be considered in the design of an affordable (needle-
free) polio vaccine, such as the use of an adjuvant serving as a 
delivery system and/or immune potentiator and an acceptable 
shelf-life, which will require formulation excipients. In the end, 
the roper designed delivery device, primary packaging, and the 
vaccine formulation together determine the storage conditions 
and shelf-life [71]. We are described here well established 
conventional vaccines such as OPV and IPV and their possible 
administrative routes. On the basis of available literature, there 
are other possible administrative routes of these vaccines.    
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(a) Dermal Immunization: 
Driven by the fact that the dermis and epidermis of the 
human skin are rich in antigen presenting cells, and the ease of 
access to the skin, there is renewed interest in dermal vaccine 
delivery. The skin’s structural and cellular composition enables 
it to function as a physical and immunological barrier, 
suggesting that delivery of vaccines to the dermal layers, rather 
than parenteral vaccine delivery, should be more efficient and 
induce protective immune responses with smaller amounts of 
vaccine antigen. At present, the ID route of immunization is only 
used for the administration of two currently-licensed vaccines: 
Bacille Calmette-Guérin (BCG vaccination against tuberculosis) 
and rabies. Currently there are three different intradermal (ID) 
delivery methods, which are used for administration purpose of 
vaccines by needle and syringe, jet injectors, and microneedles. 
Nevertheless, a PATH and WHO report reviewed the capability 
of ID delivery with vaccines against eleven diseases; including 
polio especially for IPV [73].  
 
1. Needles and syringes:  
IPV has been administrated in the developing world; 
the initial experiments of Jonas Salk anticipated its use via the 
ID route. In 1953, Salk demonstrated the immunogenicity of IPV 
administrated both intramuscularly and intradermally [70]. 
Despite these and more promising results in the mid-1950s [74-
77], the ID route was only in Denmark the most abundant route 
for IPV vaccination at that time [77, 78]. With the purpose of 
developing a more affordable IPV for the lower-income 
countries and increase its use in the post-eradication era, 
different studies investigated ID polio vaccination [79]. Trials of 
ID administration of the enhanced-potency IPV, which was, with 
its higher content of poliovirus antigen, responsible for highly 
improved seroconversion rates for all three serotypes [80], have 
been ongoing in India since the early 1990s. Satisfactory 
seroconversion rates were obtained with fractional (one-fifth) 
doses delivered ID in subjects who had been previously 
immunized [81], or had never been immunized against polio [82].  
 
2. Bio-needles: 
Bioneedles are small hollow mini-implants from 
biodegradable polymers that can be filled with antigen followed 
by a lyophilization process. After sub-cutaneous delivery, the 
implant dissolves and thereby releases the antigen. Pre-clinical 
data of IPV with different antigens showed the feasibility of 
Bioneedles as vaccine delivery system [83-86]. A first phase1 
clinical study with solid Bioneedles (without antigen) revealed 
good tolerability [87]. Besides, if formulated properly, vaccines in 
Bioneedles are thermostable, which can diminish the 
dependence on the cold-chain. 
 
(b) Novel Routes of administration only for the IPV: 
This is an exclusive for IPV better understandings of 
the feasibility of IPV use with different modes of administration 
and concomitantly with other childhood vaccines that have the 
potential to be used in sias are crucial research issues. The 
intradermal (ID) route of vaccine administration stimulates the 
immune response by delivery of vaccine antigen directly to 
dermal dendritic cells, the antigen-presenting cells that drive 
the generation of follicular T-helper cells and the subsequent 
activation and isotype-switching of naive B cells [88]. The ID 
route of administration allows a fractional dose (1/5th of the 
antigen used in intramuscular (im) administration) to elicit a 
similar immune response and therefore has the potential to 
reduce the cost of vaccination with IPV. Studies conducted to 
date with one, two and three IPV doses (and a booster dose in 
the Philippines study) have confirmed the immunogenicity of 
fractional dose ID delivery [39, 89-93]. However, although some 
studies have reported that seroconversion rates following ID 
administration of IPV for primary series or priming are lower no 
inferior to rates after a standard dose of intramuscular. IPV, 
other studies have found that seroconversion rates after ID 
administration of IPV have been inferior. Further, geometric 
mean titers and in some cases median titers induced by ID 
administration were consistently lower in all studies [89-92]. The 
benefits of disposable-syringe jet injector (DSJI) approach 
compared with needle and Syringe relates to ease of IPV 
delivery into the skin. The introduction of such an approach into 
Programs in place of intramuscular Or ID administered IPV 
would require more quantitative information. 
 
(c) Mucosal immunization only for the OPV: 
Due to their large surface area and immunological 
competence, mucosal tissues are attractive target sites for 
vaccination. An important characteristic of mucosal vaccination 
is the ability to provoke local immune responses, which already 
can protect against infection at the point of pathogen entry. 
Because mucosal surfaces are generally exposed to loads of 
environmental antigens, over-reaction of the immune system is 
prevented by tolerance mechanisms. Therefore, deliberate 
vaccination by a mucosal route can effectively induce immune 
suppression. To overcome tolerance and obtain a protective 
immune response, strong mucosal adjuvants and/or special 
antigen delivery systems are required for mucosal vaccine 
formulations unless vaccination is done with live attenuated 
viruses, like OPV.  
 
The only marketed needle-free vaccination strategy 
against polio to date is oral vaccination by OPV given as an oral 
liquid. Oral vaccination has the potential to address all the 
prerequisites for a successful needle-free vaccine and may 
facilitate vaccine efficacy when formulated appropriately [71]. 
The gastrointestinal and respiratory tracts are common sites of 
entrance for many pathogens, so the immune surveillance at 
these sites is high. On or just beneath the epithelial linings all 
the machinery is present to elicit optimal protective immunity 
in both mucosal and systemic immune compartments and to 
generate cross-protective immunity at more distant mucosal 
sites as well as systemic immunity. The mucosal immune system 
has a certain level of compartmentalization. As a result, 
depending on the inductive site and the immunogenicity of the 
antigen (local) immune responses can be induced at more 
distant effector sites In the case of polio it is expected that 
immunity in the gut will give rise to protection against polio, as 
a result, nasal vaccination, which induces mucosal immunity in 
the gut (that is more distant from the inductive site), is an 
interesting vaccination route for polio vaccination. 
 
1. Novel mucosal vaccine delivery nasal vaccination: 
Intranasal vaccination can avoid degradation of 
vaccine antigen by digestive enzymes and low ph. As a result, 
nasal vaccination may require smaller doses of the antigen 
when compared to oral immunization [95]. However, for nasal 
vaccination also to date no vaccine is on the market on the basis 
of inactivated pathogens or subunits/proteins. In 2012, Cochi 
and Linkins marked that intranasal vaccination is also a possible 
way for IPV [96]. A major drawback of intranasal immunization is 
the possible deposition of antigen in the central nervous system 
through the olfactory bulbs and olfactory nerves, which can 
cause temporary facial paralysis (Bell´s palsy) [97]. This has been 
seen with a marketed virosomal influenza vaccine that was 
adjuvated by heat labile enterotoxin of E. Coli (LT) and has been 
withdrawn from the market due to this side effect. To date, no 
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efforts have been published that address nasal vaccination with 
polio vaccine formulations. Extensive reviews on nasal delivery 
of vaccines are available: [98-100]. 
 
2. Sublingual and buccal: 
There are various traditional administrative routes 
like oral administration for OPV to induce mucosal immunity in 
human. Heleen kraan  mentioned about another possible route 
for inducing mucosal immunity against polio was used viz. 
sublingual and buccal routes. These routes have been used for 
many years for the delivery of low-molecular-weight drugs to 
the bloodstream. During the past few years, these routes 
become more and more popular in research on vaccine delivery. 
Important advantages of sublingual and buccal delivery over the 
oral route are the relatively low enzymatic activity in the mouth, 
and avoidance of the low gastric pH, which could affect the 
antigen [101]. 
 
CONCLUSION 
There is currently, a strong advocacy by the World 
Health Organization (WHO) for countries using only oral polio 
vaccine (OPV) to introduce inactivated polio vaccine (IPV), in 
different combinations with OPV. Introduction of IPV shares the 
contextual influences of both an existing vaccine and an entirely 
new vaccine, while previous vaccine hesitance studies have 
been on vaccine hesitancy to already available vaccines. There is 
a potential of vaccine hesitancy towards IPV when introduced 
and OPV is still retained in the immunization schedule, 
especially if the clinical reasons behind introduction of IPV are 
not adequately disseminated to the people. 
As far as improvement in existing OPV formulations or 
development of ‘novel’ OPV is concerned, the research has 
reached almost to a ‘dead end’ since oral vaccine is on its way of 
phasing out gradually from the global usage under cover of IPV. 
In spite of this, researchers are also trying to explore other 
possible administrative routes of these vaccines, which may 
comparative better in way of effectiveness, safe and potent for 
candidates. However, the GPEI will stockpile and utilize 
monovalent OPVs during post-eradication era to deal with any 
new outbreaks of wild or vaccine viruses. 
In conclusion, thanks to these vaccines, the world is 
now on the verge of eradication of yet another vaccine 
preventable disease after smallpox. Perhaps the success could 
have been achieved much earlier, and with less intensive effort 
had different tactics were adopted right from the beginning to 
tackle limitations of these two vaccines . Nevertheless, the fact 
remains that the transmission of all types of WPVs has almost 
been halted globally from all the countries barring two. Now the 
GPEI has to expedite WPV elimination from the remaining 
countries along with efficient removal of vaccine polioviruses 
contained in OPV under cover of universal IPV use in a globally 
synchronised manner so that the gains achieved so far are made 
permanent. 
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